Novel therapies.
New hope.
We’re developing treatments that target human disease at the molecular level.
What we do
Our focus? Working with ribose-based molecules, we use structure-guided design to generate safe and effective drug candidates—like our oral ENPP1 inhibitor treatment that’s currently in Phase 2 clinical trials.
Why we do it
We’re driven to find solutions for unmet medical needs—particularly in oncology and virology—making discoveries that can result in first-in-class drugs and best-in-class treatments and recovery outcomes.
Combating respiratory viral infections
Influenza alone kills an average of 700,000 people each year from respiratory disease or cardiovascular disease.³
How we do it
We combine uncommon chemistry and structural biology expertise with novel protein targets, and the outcome is a not-too-distant future with entirely new classes of disease-fighting drugs.
Our science
High methodology standards
The Riboscience Nucleoside Platform explores promising ribose-derived molecules that access unique targets in human disease—and that can ultimately produce treatments that are more effective, safe, overcome immune tolerance, and could even induce/activate immunity.
Our approach
Patient impact is our biggest metric
We generate high-quality data with our proprietary library of nucleosides to find therapeutics with the highest potential for safe, beneficial treatments that improve people’s lives.
More resources
Contact us
Join our team
News &
publications
